Six of these 11 cytokines (IFNGR1, TNFRSF19L, GHR, SLAMF8, FR-beta, and integrin alpha-5) have the potential to be novel serum biomarkers for the early detection and prognosis of GC, according to the findings, which collectively imply that these 11 cytokines may have a role in the occurrence and progression of GC. The gene discussed is GHR; the disease is gastric cancer.